OPN-2853 Reduces Spleen Size in Patients with Advanced Myelofibrosis (Businesswire) - Dec 8, 2025 - "As of October 2025, 29 patients had been enrolled across multiple sites in the United Kingdom. Fourteen patients were treated with 40 mg of OPN-2853 and 15 patients were treated with 80 mg of OPN-2853 added to ruxolitinib. In 16 of 26 evaluable patients, there was a 50% or greater reduction of their palpable spleen length on treatment when compared to baseline....The combination dose has been well tolerated, and the majority of patients have completed eight cycles of combination treatment."
P2 data • Myelofibrosis
|